View Older Stories View More Recent Stories

Sep 27, 2019 04:15PM AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction
Sep 26, 2019 08:00PM AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Acros
Sep 23, 2019 03:01AM AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkins
Sep 6, 2019 10:43AM AbbVie Declares Quarterly Dividend
Aug 29, 2019 08:46AM AbbVie (ABBV) Discontinues Rova-T After No Surviable Benefit Versus Placebo in SCLC
Aug 29, 2019 08:45AM AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
Aug 27, 2019 08:00AM AbbVie to Present at the Morgan Stanley Healthcare Conference
Aug 16, 2019 12:43PM AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
Aug 5, 2019 08:30AM AbbVie (ABBV) Submits NDA to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Aug 5, 2019 08:30AM AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Jul 26, 2019 07:42AM AbbVie Reports Second-Quarter 2019 Financial Results
Jul 26, 2019 07:06AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with R/R MM
Jul 15, 2019 08:02AM AbbVie (ABBV) Announces Acquisition of Mavupharma
Jul 15, 2019 08:00AM AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
Jul 11, 2019 08:00AM AbbVie to Host Second-Quarter 2019 Earnings Conference Call
Jun 25, 2019 06:45AM AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in $63 Billion Deal
Jun 25, 2019 06:42AM AbbVie to Acquire Allergan in Transformative Move for Both Companies
Jun 24, 2019 08:47AM AbbVie (ABBV) Reports FDA to Lift Partial Clinical Hold on CANOVA (M13-494), a Phase 3 Study of Venetoclax
Jun 24, 2019 08:45AM AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
Jun 20, 2019 01:45PM AbbVie Declares Quarterly Dividend
Jun 13, 2019 05:52AM AbbVie (ABBV) Highlights New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks
Jun 12, 2019 06:00PM New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
Jun 11, 2019 07:13AM AbbVie (ABBV) Says New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI Maintains Complete Skin Clearance
Jun 11, 2019 07:00AM New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
Jun 7, 2019 08:00AM AbbVie to Present at the Goldman Sachs Global Healthcare Conference
Jun 4, 2019 11:09AM AbbVie (ABBV) Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated CLL
Jun 4, 2019 11:09AM AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
May 30, 2019 08:48AM AbbVie (ABBV) Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA
May 30, 2019 08:45AM AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings
May 17, 2019 08:46AM AbbVie (ABBV) Provides Update on Depatuxizumab Mafodotin, IDMC Recommended Study be Stopped due to Lack of Survival Benefit
May 17, 2019 08:45AM AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
May 15, 2019 02:20PM AbbVie (ABBV) Announces FDA Approval of VENCLEXTA as Chemotherapy-Free Combination Regimen for Previously Untreated CLL Patients
May 15, 2019 02:19PM AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
May 14, 2019 08:35AM AbbVie (ABBV) Resolves HUMIRA U.S. Patent Litigation with BI
May 14, 2019 08:34AM AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
May 14, 2019 08:00AM AbbVie to Present at the UBS Global Healthcare Conference
Apr 30, 2019 07:47AM AbbVie (ABBV) Announces EC Approves SKYRIZI for Treatment of Moderate to Severe Plaque Psoriasis
Apr 30, 2019 07:45AM European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Apr 30, 2019 07:08AM AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
Apr 25, 2019 07:42AM AbbVie Reports First-Quarter 2019 Financial Results
Apr 23, 2019 06:19PM AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Apr 3, 2019 08:00AM AbbVie to Host First-Quarter 2019 Earnings Conference Call
Mar 26, 2019 01:00AM AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Jap
Mar 19, 2019 08:46AM AbbVie (ABBV) Announces Partial Clinical Hold on VENCLEXTA/VENCLYXTO Trials
Mar 19, 2019 08:45AM AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program
Mar 7, 2019 08:47AM AbbVie (ABBV) Announces Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated CLL Patients
Mar 7, 2019 08:46AM AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients
Mar 1, 2019 08:00AM AbbVie to Present at the Barclays Global Healthcare Conference
Mar 1, 2019 07:06AM AbbVie (ABBV) Receives CHMP Positive Opinion for Risankizumab for Treatment of Moderate to Severe Plaque Psoriasis
Mar 1, 2019 07:00AM AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
View More Recent Stories View Older Stories